-
公开(公告)号：US20080160035A1
公开(公告)日：2008-07-03
申请号：US11906517
申请日：2007-10-02
申请人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Dina M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
发明人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Dina M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
IPC分类号： A61K39/395 , C07K16/18 , C12N15/00 , A61P1/00 , A61P17/00 , A61P19/00 , A61P9/00 , C12N5/06 , C12P21/04
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or antibody fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance.
摘要翻译： 通过表面等离振子共振测量的分离的人抗体或其抗体片段，其结合人白细胞介素-4受体α（hIL-4Ralpha）具有小于200pM的亲和常数（K SUB）。
-
62.发明授权公开(公告)号：US07374757B2
公开(公告)日：2008-05-20
申请号：US11016097
申请日：2004-12-17
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
摘要翻译： 公开了具有改善的药代动力学的修饰的嵌合多肽。 具体地，公开了已经以改善其药代动力学特征的方式修饰的修饰的嵌合Flt1受体多肽。 还公开了制备和使用修饰的多肽的方法，包括但不限于使用修饰的多肽来降低或抑制哺乳动物的血浆渗透和/或血管通透性。
-
公开(公告)号：US07070959B1
公开(公告)日：2006-07-04
申请号：US10009852
申请日：2000-05-23
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
-
公开(公告)号：US20120135010A1
公开(公告)日：2012-05-31
申请号：US13309594
申请日：2011-12-02
申请人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
发明人： Sean Stevens , Tammy T. Huang , Joel H. Martin , Jeanette L. Fairhurst , Ashique Rafique , Marcela Torres , Kevin J. Pobursky , Raymond W. Leidich , Joan A. Windsor , Warren R. Mikulka , Diana M. Ahrens , Ergang Shi , Nicholas J. Papadopoulos
CPC分类号： C07K16/2866 , A61K2039/505 , C07K2317/21 , C07K2317/73 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or antigen binding fragment thereof which binds to human interleukin-4 receptor alpha (hIL-4Rα) with an affinity constant (KD) of less than 200 pM, as measured by surface plasmon resonance, is provided.
摘要翻译： 提供了通过表面等离振子共振测量的以小于200pM的亲和常数（KD）结合人白细胞介素-4受体α（hIL-4Rα）的分离的人抗体或其抗原结合片段。
-
65.发明授权Isolated nucleic acid molecules encoding a fusion protein capable of binding VEGF 有权分离编码能够结合VEGF的融合蛋白的核酸分子公开(公告)号：US08084234B2
公开(公告)日：2011-12-27
申请号：US12715128
申请日：2010-03-01
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
摘要翻译： 公开了具有改善的药代动力学的修饰的嵌合多肽。 具体地，公开了已经以改善其药代动力学特征的方式修饰的修饰的嵌合Flt1受体多肽。 还公开了制备和使用修饰的多肽的方法，包括但不限于使用修饰的多肽来降低或抑制哺乳动物的血浆渗透和/或血管通透性。
-
公开(公告)号：US08075887B2
公开(公告)日：2011-12-13
申请号：US12556605
申请日：2009-09-10
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
摘要翻译： 本发明提供了治疗一种或多种通过降低白细胞介素-4（IL-4）活性而改善，抑制或改善的疾病或病症的方法。 本发明的方法包括向患者施用特异性结合人IL-4受体的抗体或其抗原结合片段。
-
67.发明申请公开(公告)号：US20100221782A1
公开(公告)日：2010-09-02
申请号：US12715128
申请日：2010-03-01
CPC分类号： C07K14/71 , A61K38/00 , C07K16/22 , C07K19/00 , C07K2319/00 , C07K2319/30
摘要： Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal.
摘要翻译： 公开了具有改善的药代动力学的修饰的嵌合多肽。 具体地，公开了已经以改善其药代动力学特征的方式修饰的修饰的嵌合Flt1受体多肽。 还公开了制备和使用修饰的多肽的方法，包括但不限于使用修饰的多肽来降低或抑制哺乳动物的血浆渗透和/或血管通透性。
-
公开(公告)号：US20100047254A1
公开(公告)日：2010-02-25
申请号：US12556605
申请日：2009-09-10
IPC分类号： A61K39/395
CPC分类号： C07K16/2866 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/76 , C07K2317/92
摘要： The present invention provides methods for treating one or more diseases or disorders which are improved, inhibited or ameliorated by reducing interleukin-4 (IL-4) activity. The methods of the invention comprise administering to a patient an antibody, or antigen-binding fragment thereof, which specifically binds to a human IL-4 receptor.
摘要翻译： 本发明提供了治疗一种或多种通过降低白细胞介素-4（IL-4）活性而改善，抑制或改善的疾病或病症的方法。 本发明的方法包括向患者施用特异性结合人IL-4受体的抗体或其抗原结合片段。
-
公开(公告)号：US20090142354A1
公开(公告)日：2009-06-04
申请号：US12371159
申请日：2009-02-13
IPC分类号： A61K39/395 , C07K16/18
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDll4) and blocks hDll4 binding to a Notch receptor. The human anti-hDll4 antibody or antibody fragment binds dimeric hDll4 with an affinity of 75 pM or better, as measured by surface plasmon resonance.
摘要翻译： 分离的人抗体或人抗体的片段，其特异性结合人类δ样配体4（hDll4）并阻断hDll4与Notch受体的结合。 通过表面等离振子共振测量，人抗hDll4抗体或抗体片段以75pM或更好的亲和力结合二聚体hDll4。
-
公开(公告)号：US07534868B1
公开(公告)日：2009-05-19
申请号：US12371159
申请日：2009-02-13
IPC分类号： C07K16/00
CPC分类号： C07K16/18 , A61K2039/505 , C07K16/22 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/734 , C07K2317/76 , C07K2317/92
摘要： An isolated human antibody or a fragment of a human antibody which specifically binds to human delta-like ligand 4 (hDII4) and blocks hDII4 binding to a Notch receptor. The human anti-hDII4 antibody or antibody fragment binds dimeric hDII4 with an affinity of 75 pM or better, as measured by surface plasmon resonance.
摘要翻译： 特异性结合人类δ样配体4（hDII4）并阻断hDII4与Notch受体结合的分离的人抗体或人抗体片段。 如通过表面等离振子共振测量，人抗hDII4抗体或抗体片段以75pM或更好的亲和力结合二聚体hDII4。
-
-
-
-
-
-
-
-
-
搜索结果
73 条记录 (耗时 0.04 秒)
